
ImmunityBio, Inc.: shareholders and insiders
Price
$5.98
November 16, 2026Market cap $6.1B
What Ploutos Investor adds for ImmunityBio
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 17, 2025 to Oct 6, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$9.5M
3 people
From Nov 17, 2025 to Nov 17, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
- Oct 5, 2026Barry J. SimonDirectorKind10b5-1
- Oct 2, 2026Cheryl CohenDirectorKind10b5-1
- Oct 2, 2026Cheryl CohenDirectorKind10b5-1
- Jul 2, 2026Cheryl CohenDirectorKind10b5-1
- Jul 2, 2026Cheryl CohenDirectorKind10b5-1
- Jul 1, 2026Christobel SeleckyDirectorKind10b5-1
- Jul 1, 2026Christobel SeleckyDirectorKind10b5-1
- Jul 1, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 30, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 30, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 30, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 29, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 29, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 29, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 29, 2026Christobel SeleckyDirectorKind10b5-1
- Jun 24, 2026Barry J. SimonDirectorKind10b5-1
- Jun 4, 2026Barry J. SimonDirectorKind10b5-1
- Feb 24, 2026Barry J. SimonKind10b5-1
- Feb 23, 2026Barry J. SimonKind10b5-1
- Feb 23, 2026Christobel SeleckyKind10b5-1
- Feb 20, 2026Barry J. SimonKind10b5-1
- Jan 20, 2026Barry J. SimonKind10b5-1
- Jan 20, 2026Barry J. SimonKind10b5-1
- Jan 20, 2026Christobel SeleckyKind10b5-1
- Jan 16, 2026Christobel SeleckyKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 5, 2026 | Barry J. SimonDirector | 10b5-1 | 25.0K | $10.75 | $268.8K | Form 4 |
| Oct 2, 2026 | Cheryl CohenDirector | 10b5-1 | 56.0K | $2.98 | $166.8K | Form 4 |
| Oct 2, 2026 | Cheryl CohenDirector | 10b5-1 | 81.1K | $10.50 | $851.1K | Form 4 |
| Jul 2, 2026 | Cheryl CohenDirector | 10b5-1 | 56.0K | $2.98 | $166.8K | Form 4 |
| Jul 2, 2026 | Cheryl CohenDirector | 10b5-1 | 131.2K | $9.50 | $1.2M | Form 4 |
| Jul 1, 2026 | Christobel SeleckyDirector | 10b5-1 | 35.1K | $2.98 | $104.5K | Form 4 |
| Jul 1, 2026 | Christobel SeleckyDirector | 10b5-1 | 124.4K | $2.99 | $372.0K | Form 4 |
| Jul 1, 2026 | Christobel SeleckyDirector | 10b5-1 | 159.5K | $9.02 | $1.4M | Form 4 |
| Jun 30, 2026 | Christobel SeleckyDirector | 10b5-1 | 700 | $2.98 | $2.1K | Form 4 |
| Jun 30, 2026 | Christobel SeleckyDirector | 10b5-1 | 300 | $2.99 | $897 | Form 4 |
| Jun 30, 2026 | Christobel SeleckyDirector | 10b5-1 | 1,000 | $9.00 | $9.0K | Form 4 |
| Jun 29, 2026 | Christobel SeleckyDirector | 10b5-1 | 32.2K | $2.98 | $95.9K | Form 4 |
| Jun 29, 2026 | Christobel SeleckyDirector | 10b5-1 | 33.5K | $2.99 | $100.3K | Form 4 |
| Jun 29, 2026 | Christobel SeleckyDirector | 10b5-1 | 30.0K | $2.84 | $85.2K | Form 4 |
| Jun 29, 2026 | Christobel SeleckyDirector | 10b5-1 | 95.7K | $9.01 | $862.2K | Form 4 |
| Jun 24, 2026 | Barry J. SimonDirector | 10b5-1 | 25.0K | $7.88 | $196.9K | Form 4 |
| Jun 4, 2026 | Barry J. SimonDirector | 10b5-1 | 23.0K | $7.18 | $165.3K | Form 4 |
| Feb 24, 2026 | Barry J. Simon | 10b5-1 | 75.0K | $12.01 | $900.8K | Form 4 |
| Feb 23, 2026 | Barry J. Simon | 10b5-1 | 165.0K | $10.25 | $1.7M | Form 4 |
| Feb 23, 2026 | Christobel Selecky | 10b5-1 | 25.0K | $10.00 | $250.0K | Form 4 |
| Feb 20, 2026 | Barry J. Simon | 10b5-1 | 10.0K | $9.25 | $92.5K | Form 4 |
| Jan 20, 2026 | Barry J. Simon | 10b5-1 | 77.0K | $6.54 | $503.4K | Form 4 |
| Jan 20, 2026 | Barry J. Simon | 10b5-1 | 75.0K | $7.88 | $591.0K | Form 4 |
| Jan 20, 2026 | Christobel Selecky | 10b5-1 | 25.0K | $7.51 | $187.8K | Form 4 |
| Jan 16, 2026 | Christobel Selecky | 10b5-1 | 50.0K | $5.00 | $250.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 5, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by IBRX's officers and directors from 2015 up to November 16, 2025, 11 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 6 more, back to 2015
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Cambridge Equities, LPwith 5 more personsShare of class64.8%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Cambridge Equities, LPwith 5 more persons | 64.8% | 746M | Aug 6, 20263 filings since Nov 10, 2025 | 13D/A |
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter-8.1%
- Millennium Mgmt (Englander)In the quarter+293%
- Renaissance TechnologiesIn the quarter
- Citadel Advisors (Griffin)In the quarter-55%
- AQR CapitalIn the quarter+235%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 11.55M | -8.1% | $101M | 0.06% |
| Millennium Mgmt (Englander) | 5.58M | +293% | $49M | 0.03% |
| Renaissance Technologies | – | – | 0.01% | |
| Citadel Advisors (Griffin) | 136.0K | -55% | $1.2M | 0.00% |
| AQR Capital | 222.9K | +235% | $2.0M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 12.0% of its shares outstanding were held short, -0.9% since the report before.
- Shares held short
- 123M
- 12.0%
- Since the report before124M on Sep 30, 2026
- -0.9%
- 7.2
- 17.19M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 79%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 41.92M
- Nov 15, 2023: Shares held short 35.66M
- Nov 30, 2023: Shares held short 36.14M
- Dec 15, 2023: Shares held short 37.84M
- Dec 29, 2023: Shares held short 40.52M
- Jan 12, 2024: Shares held short 41.93M
- Jan 31, 2024: Shares held short 43.93M
- Feb 15, 2024: Shares held short 47.14M
- Feb 29, 2024: Shares held short 51.55M
- Mar 15, 2024: Shares held short 53.25M
- Mar 28, 2024: Shares held short 54.77M
- Apr 15, 2024: Shares held short 54.84M
- Apr 30, 2024: Shares held short 55.14M
- May 15, 2024: Shares held short 53.43M
- May 31, 2024: Shares held short 53.47M
- Jun 14, 2024: Shares held short 53.44M
- Jun 28, 2024: Shares held short 49.08M
- Jul 15, 2024: Shares held short 48.48M
- Jul 31, 2024: Shares held short 46.77M
- Aug 15, 2024: Shares held short 49.18M
- Aug 30, 2024: Shares held short 51.29M
- Sep 13, 2024: Shares held short 50.74M
- Sep 30, 2024: Shares held short 52.68M
- Oct 15, 2024: Shares held short 51.58M
- Oct 31, 2024: Shares held short 52.75M
- Nov 15, 2024: Shares held short 52.05M
- Nov 29, 2024: Shares held short 49.78M
- Dec 13, 2024: Shares held short 44.41M
- Dec 31, 2024: Shares held short 50.01M
- Jan 15, 2025: Shares held short 54.54M
- Jan 31, 2025: Shares held short 55.92M
- Feb 14, 2025: Shares held short 56.96M
- Feb 28, 2025: Shares held short 60.93M
- Mar 14, 2025: Shares held short 59.54M
- Mar 31, 2025: Shares held short 63.18M
- Apr 15, 2025: Shares held short 67.18M
- Apr 30, 2025: Shares held short 68.76M
- May 15, 2025: Shares held short 73.74M
- May 30, 2025: Shares held short 72.12M
- Jun 13, 2025: Shares held short 72.36M
- Jun 30, 2025: Shares held short 76.96M
- Jul 15, 2025: Shares held short 76.98M
- Jul 31, 2025: Shares held short 77.07M
- Aug 15, 2025: Shares held short 75.18M
- Aug 29, 2025: Shares held short 75.31M
- Sep 15, 2025: Shares held short 84.56M
- Sep 30, 2025: Shares held short 73.43M
- Oct 15, 2025: Shares held short 72.56M
- Oct 31, 2025: Shares held short 73.75M
- Nov 14, 2025: Shares held short 81.06M
- Nov 28, 2025: Shares held short 88.55M
- Dec 15, 2025: Shares held short 109M
- Dec 31, 2025: Shares held short 121M
- Jan 15, 2026: Shares held short 127M
- Jan 30, 2026: Shares held short 135M
- Feb 13, 2026: Shares held short 135M
- Feb 27, 2026: Shares held short 132M
- Mar 13, 2026: Shares held short 134M
- Mar 31, 2026: Shares held short 136M
- Apr 15, 2026: Shares held short 140M
- Apr 30, 2026: Shares held short 138M
- May 15, 2026: Shares held short 133M
- May 29, 2026: Shares held short 132M
- Jun 15, 2026: Shares held short 135M
- Jun 30, 2026: Shares held short 132M
- Jul 15, 2026: Shares held short 134M
- Jul 31, 2026: Shares held short 129M
- Aug 14, 2026: Shares held short 127M
- Aug 31, 2026: Shares held short 126M
- Sep 15, 2026: Shares held short 125M
- Sep 30, 2026: Shares held short 124M
- Oct 15, 2026: Shares held short 123M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading62.8% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 62.8% of the shares in the reported trades were short sales, against 60.9% in the 14 before.
- Last 14 sessionsOct 28, 2026 – Nov 16, 2026
- 62.8%
- The 14 beforeOct 8, 2026 – Oct 27, 2026
- 60.9%
- Change
- +1.9 pts
- Short sales a dayon average, of 7.05M shares
- 4.43M
- More than atof 3,668 US-listed companies, same days
- 88%
- Median of alleight in ten from 34.7% to 63.8%
- 50.3%
- Short sales
- Oct 8, 2026: Short sales 56.8%
- Oct 9, 2026: Short sales 49.7%
- Oct 12, 2026: Short sales 62.3%
- Oct 13, 2026: Short sales 65.2%
- Oct 14, 2026: Short sales 67.2%
- Oct 15, 2026: Short sales 63.2%
- Oct 16, 2026: Short sales 63.1%
- Oct 19, 2026: Short sales 58.1%
- Oct 20, 2026: Short sales 62.1%
- Oct 21, 2026: Short sales 60%
- Oct 22, 2026: Short sales 62.3%
- Oct 23, 2026: Short sales 58.4%
- Oct 26, 2026: Short sales 61%
- Oct 27, 2026: Short sales 58.4%
- Oct 28, 2026: Short sales 60.3%
- Oct 29, 2026: Short sales 58.1%
- Oct 30, 2026: Short sales 59.1%
- Nov 2, 2026: Short sales 58.6%
- Nov 3, 2026: Short sales 58.7%
- Nov 4, 2026: Short sales 62.2%
- Nov 5, 2026: Short sales 63.3%
- Nov 6, 2026: Short sales 56.5%
- Nov 9, 2026: Short sales 71%
- Nov 10, 2026: Short sales 68.7%
- Nov 11, 2026: Short sales 61.5%
- Nov 12, 2026: Short sales 54.4%
- Nov 13, 2026: Short sales 53%
- Nov 16, 2026: Short sales 69.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
A lower bound: it counts only the 3 officers and directors with a market trade since Nov 18, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 269 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund1.02%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.61%
- IBBiShares Biotechnology ETFWeight in the fund0.26%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.20%
- IWMiShares Russell 2000 ETFWeight in the fund0.10%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.10%
- VBKVanguard Small-Cap Growth Index FundWeight in the fund0.09%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.05%
- VHTVanguard Health Care Index FundWeight in the fund0.04%
- VBVanguard Small-Cap Index FundWeight in the fund0.04%
16 of the 269 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 265
- Q4 2025: Managers 278
- Q1 2026: Managers 387
- Q2 2026: Managers 404
Institutional investors by quarter
The fund managers holding IBRX, quarter by quarter, from Q1 2019 to Q2 2025, 26 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 404 managers held 202M shares, worth $1.8B. During the quarter 66 opened a position, 49 closed one, 135 added and 99 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+29%
- State StreetIn the quarter+21%
- Vanguard Portfolio ManagementIn the quarter+9.4%
- Vanguard Capital ManagementIn the quarter+3.7%
- D.E. ShawIn the quarter-8.1%
- Two Sigma InvestmentsIn the quarter+153%
- Geode Capital ManagementIn the quarter+23%
- Millennium Mgmt (Englander)In the quarter+293%
- Northern TrustIn the quarter+42%
- Morgan StanleyIn the quarter-15%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 34.08M | +29% | $298M |
| State Street | 21.40M | +21% | $187M |
| Vanguard Portfolio Management | 17.86M | +9.4% | $156M |
| Vanguard Capital Management | 15.69M | +3.7% | $137M |
| D.E. Shaw | 11.55M | -8.1% | $101M |
| Two Sigma Investments | 11.10M | +153% | $97M |
| Geode Capital Management | 9.85M | +23% | $86M |
| Millennium Mgmt (Englander) | 5.58M | +293% | $49M |
| Northern Trust | 3.57M | +42% | $31M |
| Morgan Stanley | 3.43M | -15% | $30M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do ImmunityBio's filings show?
Who buys and sells is one part of ImmunityBio's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have IBRX's insiders bought or sold?
From Jun 5, 2026 to Oct 6, 2026 ImmunityBio's insiders bought 0 and sold $5.0M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold IBRX?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $101M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.